Clinical trial
A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetics Study of PRA023 in Healthy Volunteers
NCT04676178 is registered in ClinicalTrials.gov with Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetics Study of PRA023 in Healthy Volunteers
- Lead sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 15, 2020
- Completion date
- September 23, 2021
- Enrollment
- 69 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy